Document:

2004 Stock Incentive Plan Restricted Stock Unit Agreement

 EXHIBIT 10.5.1 
 ICAGEN, INC. 
 2004 STOCK INCENTIVE PLAN 
 RESTRICTED STOCK UNIT AGREEMENT 
 This RESTRICTED STOCK UNIT AGREEMENT (the “Agreement”), dated as of              (the “Date of Grant”), is delivered
by Icagen, Inc., a Delaware corporation (“Icagen”), to              (the “Grantee”), a director of Icagen. 
 RECITALS 
 The Icagen, Inc. 2004 Stock Incentive Plan (the “Plan”) provides for the grant of stock-based awards with respect to shares of common stock, par value $0.001 per share, of Icagen (the “Common Stock”), in accordance with
the terms and conditions of the Plan. The Board of Directors of Icagen (the “Board’), upon recommendation of the Compensation Committee of the Board (the “Committee”), has determined to make a stock-based award in the form of a
grant of restricted stock units, subject to the terms and conditions set forth in this Agreement and the Plan. The Grantee may obtain a copy of the Plan by contacting the Human Resources Manager at Icagen. 
 NOW, THEREFORE, the parties to this Agreement, intending to be legally bound hereby, agree as follows: 
 1. Grant of Restricted Stock Units. Subject to the terms and conditions set forth in this Agreement and the Plan and as of the Date of Grant, Icagen
hereby grants to the Grantee                      restricted stock units (the “Restricted Stock Units”) under the Plan. The Grantee
accepts the Restricted Stock Units and agrees to be bound by the terms and conditions of this Agreement and the Plan with respect to the Restricted Stock Units. 
 2. Restricted Unit Account. The Restricted Stock Units represent the right to receive shares of Common Stock, subject to the vesting and other terms and conditions of this Agreement, and are not
actual shares of stock. Icagen shall establish and maintain a Restricted Stock Unit account, as a bookkeeping account on its records, for the Grantee and shall record in such account the number of Restricted Stock Units granted to the Grantee. No
shares of stock shall be issued to the Grantee at the time the grant is made, and the Grantee shall not be, nor have any of the rights or privileges of, a stockholder of Icagen with respect to any Restricted Stock Units recorded in the account. The
Grantee shall not have the right to receive any dividends or other distributions with respect to Restricted Stock Units recorded in the Grantee’s account; provided, however, that the Committee may appropriately adjust the number and kind of
Restricted Stock Units in the event of a stock split, stock dividend or other change in capitalization of Icagen, as provided in the Plan. The Grantee shall not have any interest in any fund or specific assets of Icagen by reason of this award or
the Restricted Unit account established for the Grantee. 

 3. Vesting of Restricted Stock Units. 
 The Restricted Stock Units shall vest
                         (the “Vesting Date”), provided that the Grantee does not cease to serve as a member of
the Board prior to the Vesting Date. Notwithstanding the foregoing, upon a Change of Control Event, as defined in the Plan, the Restricted Stock Units shall automatically become fully vested effective immediately prior to the consummation of such
Change of Control Event. In the event of a Reorganization Event (as defined in the Plan) that is not a Change of Control Event, the provisions set forth in Section 8(c)(3)(a) of the Plan shall apply to the Restricted Stock Units. 
 4. Issuance of Common Stock. 
 (a) When the Restricted Stock Units vest as described above, such Restricted Stock Units shall no longer be subject to forfeiture. Subject to the terms of this Agreement, Icagen shall issue or cause to be
issued to the Grantee one share of Common Stock for each whole vested Restricted Stock Unit on, or as soon as practicable after, the date the Restricted Stock Units vest in accordance with Paragraph 3 (but in any event by the thirtieth
(30th) day following such date), subject to the
satisfaction of the Grantee’s tax withholding obligations as described below. 
 (b) All obligations of Icagen and rights
of Grantee under this Agreement shall be subject to the rights of Icagen as set forth in the Plan to withhold any amounts that may be required to be withheld by Icagen for applicable taxes. In the event Icagen determines it has tax withholding
obligations with respect to the Restricted Stock Units, the Grantee agrees to arrange for the satisfaction of the minimum amount of such tax withholding obligations in a manner acceptable to Icagen as a condition to the issuance of the shares of
Common Stock under Paragraph 4(a). 
 (c) The obligation of Icagen to deliver shares hereunder shall also be subject to the
condition that if at any time the Committee shall determine in its discretion that the listing, registration or qualification of the shares of Common Stock upon any securities exchange or under any state or federal law, or the consent or approval of
any governmental regulatory body, is necessary or desirable as a condition of, or in connection with, the issue of shares, the shares may not be issued in whole or in part unless such listing, registration, qualification, consent or approval shall
have been effected or obtained free of any conditions not acceptable to the Committee. The issuance of shares of Common Stock to the Grantee pursuant to this Agreement is subject to any applicable taxes and other laws or regulations of the United
States or of any state having jurisdiction thereof. 
 (d) The Grantee agrees to be bound by Icagen’s policies regarding
transfer of shares of Common Stock and understands that there may be certain times during the year in which the Grantee will be prohibited from selling, transferring, pledging, donating, assigning, mortgaging, hypothocating or encumbering shares.

 5. Termination of Restricted Stock Units. If the Grantee ceases to serve as a member of the Board prior to the Vesting Date for any
reason, the Restricted Stock Units shall automatically terminate and shall be forfeited as of the date the Grantee ceases to serve as a director. No payment or issuance of Common Stock shall be made with respect to any Restricted Stock Units that
terminate as described in this Paragraph 5. 
  

 2 

 6. Grant Subject to Plan Provisions. This grant is made pursuant to the Plan, the terms of which are
incorporated herein by reference, and in all respects shall be interpreted in accordance with the Plan. The grant and payment of the Restricted Stock Units are subject to interpretations, regulations and determinations concerning the Plan
established from time to time by the Committee in accordance with the provisions of the Plan, including, but not limited to, provisions pertaining to (i) rights and obligations with respect to withholding taxes, (ii) the registration,
qualification or listing of the shares issued under the Plan, (iii) changes in capitalization of Icagen, and (iv) other requirements of applicable law. The Committee shall have the authority to interpret and construe the Restricted Stock
Units pursuant to the terms of the Plan, and its decisions shall be conclusive as to any questions arising hereunder. 
 7. No Right to
Continued Board Service. The grant of the Restricted Stock Units shall not confer upon the Grantee any right to continued service as a director of the Company. 
 8. No Stockholder Rights. Neither the Grantee, nor any person entitled to receive payment in the event of the Grantee’s death, shall have any of the rights and privileges of a stockholder with
respect to shares of Common Stock, until certificates for shares have been issued upon payment of Restricted Stock Units. 
 9. Assignment
and Transfers. Except as the Committee may otherwise permit pursuant to the Plan, the rights and interests of the Grantee under this Agreement may not be sold, assigned, encumbered or otherwise transferred except, in the event of the death of
the Grantee, by will or by the laws of descent and distribution. In the event of any attempt by the Grantee to alienate, assign, pledge, hypothecate, or otherwise dispose of the Restricted Stock Units or any right hereunder, except as provided for
in this Agreement, or in the event of the levy or any attachment, execution or similar process upon the rights or interests hereby conferred, Icagen may terminate the Restricted Stock Units by notice to the Grantee, and the Restricted Stock Units
and all rights hereunder shall thereupon become null and void. The rights and protections of Icagen hereunder shall extend to any successors or assigns of Icagen, and to Icagen’s parents, subsidiaries, and affiliates, as applicable. This
Agreement may be assigned by Icagen without the Grantee’s consent. 
 10. Agreement in Connection with Public Offering. The Grantee
agrees, in connection with an underwritten public offering of Icagen’s securities pursuant to a registration statement under the Securities Act of 1933, as amended, (i) not to sell, make short sale of, loan, grant any options for the
purchase of, or otherwise dispose of any shares of Common Stock held by the Grantee (other than those shares included in the offering) without the prior written consent of Icagen or the underwriters managing such underwritten public offering of
Icagen’s securities for such number of days (not to exceed 180 days) from the effective date of such registration statement as the managing underwriters or Icagen may require, and (ii) to execute any agreement reflecting clause
(i) above as may be requested by Icagen or the managing underwriters at the time of such offering. 
  

 3 

 11. Unfunded Arrangement. The Grantee’s rights to receive payments under this Agreement shall be
no greater than the right of an unsecured general creditor of Icagen. All payments shall be made from the general assets of Icagen, and no special or separate fund shall be established and no segregation of assets shall be made to assure payment.

 12. Tax Consequences. The Grantee acknowledges that the Grantee may be subject to adverse tax consequences as a result of the
issuance, vesting and/or distribution of the Restricted Stock Units and/or the Common Stock and understands that the Grantee should consult a tax advisor as to the tax consequences of the Restricted Stock Units and subsequent distribution of Common
Stock. To the extent that this Agreement, the issuance and vesting of the Restricted Stock Units and/or distribution of Common Stock as set forth in this Agreement is subject to Section 409A of the Internal Revenue Code of 1986, as amended, and
any regulations promulgated thereunder (the “Code”), the Grantee agrees to cooperate and work together with Icagen to timely amend this Grant to comply with Section 409A of the Code as necessary. 
 13. Applicable Law. The validity, construction, interpretation and effect of this Agreement shall be governed by and construed in accordance with the
laws of the State of Delaware, without giving effect to the conflicts of laws provisions thereof. 
 14. Notice. Any notice to Icagen
provided for in this Agreement shall be addressed to Icagen, Inc. in care of the Human Resources Manager, at the corporate headquarters of Icagen, and any notice to the Grantee shall be addressed to such Grantee at the current address shown on the
payroll of Icagen, or to such other address as the Grantee may designate to Icagen, in writing. Any notice shall be delivered by hand, sent by telecopy or enclosed in a properly sealed envelope addressed as stated above, registered and deposited,
postage prepaid, in a post office regularly maintained by the United States Postal Service. 
  

 4 

 IN WITNESS WHEREOF, Icagen has caused its duly authorized officer to execute this Restricted
Stock Unit Agreement, and the Grantee has placed his signature hereon, effective as of the Date of Grant. 
  

			
	ICAGEN, INC.
		
	 By: 
	 	  

	 Name:
	 	
	 Title:
	 	

 ACCEPTANCE: 
 I hereby accept the award of Restricted Stock Units described in this Agreement, and I agree to be bound by the terms of the Plan and this Agreement. I hereby agree that all of the decisions and determinations of the Committee with respect
to the Restricted Stock Units shall be final and binding. 
  

	
	  

	 Grantee

	
	  

	 Date

  

 5Summary of Director Compensation

 EXHIBIT 10.6 
 ICAGEN, INC. 
 Summary of Director Compensation 

 Compensation of our Directors 
 Icagen, Inc. (the “Company”) reimburses non-employee directors for out-of-pocket expenses they incur in attending Board and committee meetings and pays each non-employee director an annual
retainer fee. The Chairmen of the Company’s Audit, Compensation and Nominating/Corporate Governance Committees receive an additional annual retainer. For 2008, the annual retainer fee for all non-employee directors was $25,000, and the annual
retainer for the Chairmen of the Audit, Compensation and Nominating/Corporate Governance Committee was $10,000, $3,000, and $3,000, respectively. On March 5, 2009, the Company’s Board of Directors, upon recommendation of the Compensation
Committee, approved a 50% reduction in annual retainer fees from their 2008 levels. Accordingly, the annual retainer fees for 2009 for all non-employee directors was $12,500 and the annual retainer fee for the Chairmen of the Audit, Compensation and
Nominating/Corporate Governance Committees was $5,000, $1,500 and $1,500, respectively. On December 8, 2009, the Company’s Board of Directors, upon recommendation of the Compensation Committee, approved for 2010 a 50% reduction in annual
retainer fees from their 2008 levels. Accordingly, the annual retainer fee for 2010 for all non-employee directors will continue to be $12,500, the annual retainer fee for the Chairman of the Audit, Compensation and Nominating/Corporate Governance
Committees will continue to be $5,000, $1,500 and $1,500, respectively. 
 The Company also pays each non-employee director
$1,000 for attendance at each Board meeting in which he or she participates in person or $500 if attendance is by telephone. Each non-employee director also receives $1,000 for each meeting of a committee of the Board that is held on a day other
than the day of any meeting of the full Board of Directors if he or she participates in person, or $500 if attendance is by telephone. Directors who are also the Company’s employees do not receive any compensation in their capacities as
directors. 
 Upon the commencement of service on the Board by any non-employee director, the Company grants to such person a
non-statutory stock option to purchase the number of shares of the Company’s common stock equal to the product of (i) 10,000 shares of the Company’s common stock divided by 12 and (ii) the number of full calendar months between the date of
commencement of service and the month in which the Company’s next annual meeting of stockholders is scheduled to occur. Each of the Company’s non-employee directors is also automatically granted a non-statutory stock option to purchase
10,000 shares of the Company’s common stock every year on the first business day after the Company’s Annual Meeting of Stockholders. In addition, the Company’s Chairman of the Board of Directors receives a non-statutory stock option
to purchase 20,000 additional shares of the Company’s common stock every year on the first business day after the Company’s Annual Meeting of Stockholders. All of these options are fully vested on the date of grant and have exercise prices
equal to the closing price of the Company’s common stock on the date of grant. 
 To compensate non-employee directors for
the reduction in annual retainer fees for 2009 discussed above, on March 5, 2009, the Board of Directors, upon recommendation of the Compensation Committee, granted each of the Company’s non-employee directors (other than Dennis B. Gillings,
CBE, Ph.D.), a number of restricted stock units, or RSUs, equal to (i) the dollar amount by which the annual retainer fee for 2008 was reduced, taking into account fees received by such director for service as a chairman of a committee of the Board,
divided by (ii) $0.47, the closing price of the Company’s common stock on that date. Each RSU represents the right to receive in the future one share of the Company’s common stock, subject to the terms and conditions of the applicable
restricted stock unit agreement. These RSUs vested in full on December 31, 2009. To compensate non-employee directors for the reduction in annual retainer fees for 2010 described above, on December 8, 2009, the Board of Directors, upon
recommendation of the Compensation Committee, granted each of the Company’s non-employee directors (other than Dr. Gillings) on January 4, 2010 a number of RSUs equal to (i) the dollar amount by which the annual retainer fee for 2008 was
reduced, taking into account any fees received by such director for service as a chairman of a committee of the Board, by (ii) $0.47, the closing price of the Company’s common stock on that date. Each RSU represents the right to receive in the
future one share of the Company’s common stock, subject to the terms and conditions of the applicable restricted stock unit agreement. These RSUs will vest in full on December 1, 2010. If a director ceases to serve as a member of the
Company’s Board of Directors for any reason prior to that date, all RSUs will automatically terminate and be forfeited as of the date such person ceases to serve as a member of the Board. In addition, upon the occurrence of a change of control
of Icagen, each RSU will immediately become fully vested. 

 At a meeting of the Board on March 5, 2009, Dr. Gillings voluntarily declined the RSU grant
described above as well as all retainer fees and meeting attendance fees that he would otherwise be entitled to for the remainder of 2009 as compensation for his Board service. At a meeting of the Board on June 2, 2009, Anthony B. Evnin, Ph.D.,
voluntarily declined the remaining annual retainer fees that he would otherwise be entitled to for the remainder of 2009 as compensation for his board service. Also on December 8, 2009, Dr. Gillings voluntarily declined all forms of compensation for
2010 to which he would otherwise be entitled as compensation for his board service, and Dr. Evnin voluntarily declined all forms of cash compensation for 2010 to which he would otherwise be entitled for his board service. 
 The Compensation Committee and the Board of Directors of the Company periodically reevaluate compensation of the Company’s non-employee
directors and may modify such compensation as they deem appropriate.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00171-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00171-of-00352.parquet"}]]